Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  International Journal of Radiation Oncology, Biology, Physics

• Publication date

  2017-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ijrobp.2017.05.029PMID 28816141
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses

  2017cited by this paper
• Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages

  2017cited by this paper
• Abstract S5-07: Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028

  2016cited by this paper
• The Promise of the Abscopal Effect and the Future of Trials Combining Immunotherapy and Radiation Therapy.

  2016cited by this paper
• nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors

  2016cited by this paper
• Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).

  2016cited by this paper
• Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

  2016cited by this paper
• Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review.

  2016cited by this paper
• Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking?

  2016cited by this paper
• Abstract S1-04: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial

  2016cited by this paper
• HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

  2016cited by this paper
• A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab

  2015cited by this paper
• The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence

  2015cited by this paper
• The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant.

  2015cited by this paper
• In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment.

  2015cited by this paper
• Role of Local Radiation Therapy in Cancer Immunotherapy.

  2015cited by this paper
• Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.

  2015cited by this paper
• Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

  2015cited by this paper
• Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model

  2015cited by this paper
• Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.

  2015cited by this paper
• STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.

  2014cited by this paper
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014cited by this paper
• Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.

  2014cited by this paper
• Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

  2014cited by this paper
• Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

  2014cited by this paper
• Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

  2014cited by this paper
• Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

  2014cited by this paper
• Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

  2014cited by this paper
• Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

  2014cited by this paper
• Abstract 632: Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing

  2014cited by this paper
• Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

  2014cited by this paper
• PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer

  2014cited by this paper
• Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

  2014cited by this paper
• PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer

  2014cited by this paper
• The Etiology of Treatment-related Lymphopenia in Patients with Malignant Gliomas: Modeling Radiation Dose to Circulating Lymphocytes Explains Clinical Observations and Suggests Methods of Modifying the Impact of Radiation on Immune Cells

  2013cited by this paper
• Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.

  2013cited by this paper
• Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy

  2013cited by this paper
• Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

  2013cited by this paper
• Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.

  2013cited by this paper
• Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

  2013cited by this paper
• Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

  2013cited by this paper
• Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy.

  2013cited by this paper
• Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing

  2013cited by this paper
• CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer.

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• A systemic complete response of metastatic melanoma to local radiation and immunotherapy.

  2012cited by this paper
• Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.

  2012cited by this paper
• Immunologic correlates of the abscopal effect in a patient with melanoma.

  2012cited by this paper
• The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art.

  2012cited by this paper
• Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer

  2012cited by this paper
• Ipilimumab and Stereotactic Radiosurgery for Melanoma Brain Metastases

  2012cited by this paper
• Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer.

  2012cited by this paper
• Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.

  2011cited by this paper
• Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast Cancer

  2010cited by this paper
• The PD‐1 pathway in tolerance and autoimmunity

  2010cited by this paper
• Up-regulation of the Pro-inflammatory Chemokine CXCL16 is a Common Response of Tumor Cells to Ionizing Radiation

  2010cited by this paper
• Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

  2010cited by this paper
• Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody

  2009cited by this paper
• Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment.

  2009cited by this paper
• Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

  2009cited by this paper
• Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice.

  2009cited by this paper
• Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells1

  2008cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells

  2008cited by this paper
• The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy

  2007cited by this paper
• Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

  2007cited by this paper
• Calreticulin exposure dictates the immunogenicity of cancer cell death

  2007cited by this paper
• Immunostimulatory monoclonal antibodies for cancer therapy

  2007cited by this paper
• Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

  2006cited by this paper
• Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation

  2006cited by this paper
• Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.

  2005cited by this paper
• Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor1

  2005cited by this paper
• Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.

  2004cited by this paper
• Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated.

  2004cited by this paper
• Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes

  2004cited by this paper
• Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1

  2003cited by this paper
• Irradiation of Tumor Cells Up-Regulates Fas and Enhances CTL Lytic Activity and CTL Adoptive Immunotherapy

  2003cited by this paper
• PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver

  2003cited by this paper
• The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice

  2003cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication.

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• The interaction properties of costimulatory molecules revisited.

  2002cited by this paper
• Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity

  2001cited by this paper
• PD-L2 is a second ligand for PD-1 and inhibits T cell activation

  2001cited by this paper
• Irradiation induced expression of CD31, ICAM-1 and VCAM-1 in human microvascular endothelial cells.

  2000cited by this paper
• Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity1

  2000cited by this paper
• High Mobility Group 1 Protein (Hmg-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes

  2000cited by this paper
• Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer.

  1999cited by this paper
• Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

  1997cited by this paper
• Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium.

  1996cited by this paper

• Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial.

  2025cites this paper
• The role of radiotheranostics in personalized treatment for breast cancer

  2025cites this paper
• Tumor Microenvironment Dynamics of Triple-Negative Breast Cancer Under Radiation Therapy

  2025cites this paper
• The value of intervention with radiotherapy after first-line chemo-immunotherapy in locally advanced or metastatic esophageal squamous cell carcinoma: A multi-center retrospective study

  2024cites this paper
• Public neoantigens in breast cancer immunotherapy (Review)

  2024cites this paper
• Progress in research and treatment of immune checkpoints in breast cancer

  2024cites this paper
• Neoadjuvant radiotherapy in ER+, HER2+, and triple-negative -specific breast cancer based humanized tumor mice enhances anti-PD-L1 treatment efficacy

  2024cites this paper
• The Potential of PARP Inhibitors as Antitumor Drugs and the Perspective of Molecular Design.

  2024cites this paper
• Anticancer potential of active alkaloids and synthetic analogs derived from marine invertebrates.

  2024cites this paper
• Nanobiotechnology‐mediated radioimmunotherapy treatment for triple‐negative breast cancer

  2023cites this paper
• DNA repair in tumor radioresistance: insights from fruit flies genetics

  2023cites this paper
• Cavitation-Mediated Immunomodulation and Its Use with Checkpoint Inhibitors

  2023cites this paper
• New immunotherapeutic approaches for cancer treatment.

  2023cites this paper
• Challenges in the combination of radiotherapy and immunotherapy for breast cancer

  2023cites this paper
• Effects of whole-brain radiation therapy on the blood–brain barrier in immunocompetent and immunocompromised mouse models

  2023cites this paper
• Protein Phosphatase 1 Regulatory Subunit 3: A Prognostic Biomarker in Stomach Adenocarcinoma

  2022cites this paper
• Manipulation of PD‐L1 Endosomal Trafficking Promotes Anticancer Immunity

  2022cites this paper
• Immunotherapy and immunobiomarker in breast cancer: current practice and future perspectives.

  2022cites this paper
• Radioimmunotherapy in HPV-Associated Head and Neck Squamous Cell Carcinoma

  2022cites this paper
• The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment

  2022cites this paper
• Efficacy of radiotherapy combined with immune checkpoint inhibitors in patients with melanoma: a systemic review and meta-analysis

  2022cites this paper
• Application of Noninvasive Imaging to Combined Immune Checkpoint Inhibitors for Breast Cancer: Facts and Future

  2022cites this paper
• Immunogenomic Analyses of the Prognostic Predictive Model for Patients With Renal Cancer

  2021cites this paper
• Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer

  2021cites this paper
• The Updated Status and Future Direction of Immunotherapy Targeting B7-H1/PD-1 in Osteosarcoma

  2021cites this paper
• Correlations Between Tumor Mutation Burden and Immunocyte Infiltration and Their Prognostic Value in Colon Cancer

  2021cites this paper
• Predicting the Level of Tumor-Infiltrating Lymphocytes in Patients With Breast Cancer: Usefulness of Mammographic Radiomics Features

  2021cites this paper
• Molecular Subtypes and CD4+ Memory T Cell-Based Signature Associated With Clinical Outcomes in Gastric Cancer

  2021cites this paper
• Coordinated regulation of immune contexture: crosstalk between STAT3 and immune cells during breast cancer progression

  2021cites this paper
• Outcomes after breast-conserving surgery or mastectomy in patients with triple-negative breast cancer: meta-analysis.

  2021cites this paper
• Radiotherapy enhanced by NBTXR3 nanoparticles overcomes anti-PD1 resistance and evokes abscopal effects.

  2021cites this paper
• Prognostic Factors for Advanced/Recurrent Breast Cancer Treated With Immune-cell Therapy

  2021cites this paper
• CMAR_A_285560 757..764

  2021cites this paper
• Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer

  2021cites this paper
• Classes of therapeutics to amplify the immune response

  2021cites this paper
• Locally Injectable Hydrogels for Tumor Immunotherapy

  2021cites this paper
• Prognostic Model Construction and Immune Microenvironment Analysis of Breast Cancer Based on Ferroptosis-Related lncRNAs

  2021cites this paper
• Cancer-Associated Fibroblasts-Derived Exosomes Suppress Immune Cell Function in Breast Cancer via the miR-92/PD-L1 Pathway

  2020cites this paper
• Promising potential of [Lu]Lu-DOTA-folate to enhance tumor response to immunotherapy—a preclinical study using a syngeneic breast cancer model

  2020cites this paper
• Identification of a 15-pseudogene based prognostic signature for predicting survival and antitumor immune response in breast cancer

  2020cites this paper
• Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.

  2020cites this paper
• Immune Infiltrate in the Primary Tumor Predicts Effect of Adjuvant Radiotherapy in Breast Cancer; Results from the Randomized SweBCG91RT Trial

  2020cites this paper
• High-dimensional single-cell analysis delineates radiofrequency ablation induced immune microenvironmental remodeling in pancreatic cancer

  2020cites this paper
• Analysis of the expression, function, prognosis and co-expression genes of DDX20 in gastric cancer

  2020cites this paper
• Cancer-associated fibroblasts-derived exosomes suppresses immune cell function in breast cancer via miR-92/PD-L1 pathway

  2020cites this paper
• Combining radiation therapy and immunotherapy for lung cancers: a narrative review

  2020cites this paper
• IMMUNE CHECKPOINT BLOCKADE IN BREAST CANCER THERAPY

  2020cites this paper
• Radiotherapy in combination with systemic therapies for brain metastases: current status and progress

  2020cites this paper
• Promising potential of [177Lu]Lu-DOTA-folate to enhance tumor response to immunotherapy—a preclinical study using a syngeneic breast cancer model

  2020cites this paper
• Co-delivered Chemotherapeutic Doxorubicin via a Dual-functional Immunostimulatory Polymeric Prodrug for Breast Cancer Immunochemotherapy.

  2020cites this paper
• Radiation therapy for oligometastatic bone disease in breast cancer

  2020cites this paper
• Pure abscopal effect of radiotherapy in a salivary gland carcinoma: Case report, literature review, and a search for new approaches.

  2020cites this paper
• Identi cation of Protein Phosphatase 1 Regulatory Subunit 3 as a Prognostic Biomarker in Patients with Gastric Cancer

  2020cites this paper
• Mathematical modeling of cancer treatment with radiation and PD-L1 inhibitor

  2020cites this paper
• Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading

  2019cites this paper
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Management of Immunotherapy- Related Toxicities, Version 1.2019

  2019cites this paper
• Immune targets in the tumor microenvironment treated by radiotherapy

  2019cites this paper
• Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches

  2019cites this paper
• Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma.

  2019cites this paper
• The balance between breast cancer and the immune system: challenges for prognosis and clinical benefit from immunotherapies.

  2019cites this paper
• Tumor-Infiltrating Immunosuppressive Cells in Cancer-Cell Plasticity, Tumor Progression and Therapy Response

  2019cites this paper
• MOLECULAR CANCER THERAPEUTICS | CANCER BIOLOGYAND TRANSLATIONAL STUDIES PD-1/PD-L1 ImmuneCheckpoint InhibitionwithRadiation in Bladder Cancer: In Situ and Abscopal Effects

  2019cites this paper
• AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019

  2019cites this paper
• Cancer DNA vaccines: current preclinical and clinical developments and future perspectives

  2019cites this paper
• An Optogenetic Controllable T Cell System for Hepatocellular Carcinoma Immunotherapy

  2019cites this paper
• Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

  2018cites this paper
• Hypothesis: can the abscopal effect explain the impact of adjuvant radiotherapy on breast cancer mortality?

  2018cites this paper
• Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy?

  2018cites this paper
• Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy

  2018cites this paper
• SEPROGADIC – serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy

  2018cites this paper
• Cancer immunotherapy by targeting immune checkpoint receptors

  2018cites this paper
• Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.

  2018cites this paper
• The Progress of T Cell Immunity Related to Prognosis in Gastric Cancer

  2018cites this paper